> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 10 Observations in Lupin FDA-483
- URL: https://www.fdaweb.com/10-observations-in-lupin-fda-483/
- Published: 2023-04-20T12:00:00.000Z
- Updated: 2026-09-14T18:26:51.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154262

FDA has released the form FDA-483 issued following a 3/21-3/29 inspection at Lupin Limited, a drug manufacturer in Pithampur, India. The 10 inspection observations on the [form](https://www.fda.gov/media/167276/download?ref=fdaweb.com) are:

- investigations of a failure of a batch or any of its components to meet any of its specifications did not extend to other drug products that may have been associated with the specific failure or discrepancy;
- failing to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has been already distributed;
- written records of the investigation of a drug complaint do not include the findings of the investigation and the follow-up;
- employees engaged in the manufacture, processing, packing, and holding of a drug product lack the training required to perform their assigned functions;
- the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed;
- equipment for adequate control over air pressure, humidity, and temperature is not provided when appropriate for the manufacture, processing, packing, or holding of a drug product;
- substances required for equipment operations such as lubricants and coolants come in contact with drug product containers, closures, and drug products, altering the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements;
- appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel;
- procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, or followed; and
- laboratory controls do not include the establishment of scientifically sound and appropriate specifications, test procedures designed to assure that components and drug products conform to appropriate standards of identity, strength, quality, and purity.

The form indicates that four of the observations are repeated from an earlier inspection.